ParkerVision registers 13.34M shares for resale
ParkerVision, Inc. files a Prospectus Supplement registering 13,342,953 shares of Common Stock for resale by selling stockholders under its shelf prospectus.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ParkerVision, Inc. files a Prospectus Supplement registering 13,342,953 shares of Common Stock for resale by selling stockholders under its shelf prospectus. The supplement states the company will receive no proceeds from resales; cash proceeds up to $2,833,756 are possible if outstanding warrants are exercised.
The filing also attaches a Form 8-K disclosing that the Compensation Committee extended expiration dates for previously issued, fully vested nonqualified stock options for CEO Jeffrey Parker (2,660,000 options) and CFO Cynthia French (870,550 options) from August 7, 2026 to August 7, 2029. The exercise price remains $0.171 per share. The company expects a one-time non-cash share-based compensation charge of approximately $360,000.
Insights
Option extensions preserve previously granted economic terms; expect a one-time non-cash charge.
Extending the expiration dates of fully vested, nonqualified options (2,660,000 and 870,550 options) keeps the original exercise price of $0.171 while lengthening the term to August 7, 2029. The change is described as the sole modification, with no new securities issued.
The company expects to record a one-time non-cash $360,000 share-based compensation charge; the accounting impact is discrete and timing is tied to the modification date of April 22, 2026. Subsequent filings will show the actual charge in reported results.
Prospectus Supplement registers resale capacity and confirms limited issuer proceeds only from warrant exercises.
The supplement registers 13,342,953 shares for resale by selling stockholders and states the issuer will not receive proceeds from those resales. It discloses potential cash inflows of up to $2,833,756 if warrants are exercised for cash.
Use of any warrant exercise proceeds is stated as for general working capital, including litigation expenses. The supplement attaches the referenced Form 8-K dated April 22, 2026.
Key Figures
Key Terms
Prospectus Supplement regulatory
resale by selling stockholders financial
nonqualified stock options financial
warrants financial
Offering Details
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does ParkerVision's prospectus supplement (PRKR) register?
Will ParkerVision receive proceeds from the registered resales?
How much could ParkerVision receive if warrants are exercised?
What option changes did ParkerVision disclose on Form 8-K?
Will the option modifications create an accounting charge?
AI-generated analysis. How Rhea-AI works. Not financial advice.